Abstract
Background: Higher iron occurs in the substantia nigra in Parkinson's disease (PD), but its behavior over time is poorly understood. Objective: To determine if nigral iron measured by quantitative susceptibility MRI can track progression of early stages of PD. Methods: Thirty-four early-stage PD patients (disease duration < 4 yrs) and 35 matched controls were recruited. Iron content in the substantia nigra and related regions was obtained using quantitative susceptibility mapping with zero-referencing at both baseline and one-year follow-up, along with clinical metrics. Results: Of five clinic metrics and five regional iron measures, only MDS-UPDRS II (p = 0.046) and SNc iron (p = 0.004) showed significant changes for PD subjects in the one-year epoch. The changes of SNc iron also were correlated with changes of MDS-UPDRS II (p = 0.005). Conclusion: Nigral iron content measured by zero-referencing is sensitive for tracking disease progression in early-stage PD.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent that was in accordance with the Declaration of Helsinki, and the protocol was approved by the Penn State Hershey Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Funder Information Declared
